Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) EVP Ryan Savitz sold 3,044 shares of the business’s stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $90.03, for a total transaction of $274,051.32. Following the sale, the executive vice president directly owned 29,276 shares of the company’s stock, valued at approximately $2,635,718.28. The trade was a 9.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Ryan Savitz also recently made the following trade(s):
- On Thursday, November 12th, Ryan Savitz sold 17,724 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $90.56, for a total transaction of $1,605,085.44.
- On Monday, November 9th, Ryan Savitz sold 100,713 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $90.54, for a total transaction of $9,118,555.02.
- On Tuesday, November 10th, Ryan Savitz sold 2,561 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $90.14, for a total value of $230,848.54.
Dianthus Therapeutics Stock Performance
DNTH traded down $0.67 during midday trading on Friday, reaching $91.81. 681,515 shares of the company were exchanged, compared to its average volume of 942,202. The company’s fifty day moving average price is $88.45 and its 200 day moving average price is $86.56. The company has a market cap of $5.17 billion, a price-to-earnings ratio of -23.01 and a beta of 1.47. Dianthus Therapeutics, Inc. has a one year low of $34.29 and a one year high of $117.88.
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.13. Dianthus Therapeutics had a negative return on equity of 19.68% and a negative net margin of 7,436.50%. The firm had revenue of $1.21 million during the quarter, compared to the consensus estimate of $0.46 million. As a group, sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -3.55 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the stock. 49 Wealth Management LLC bought a new position in Dianthus Therapeutics during the third quarter valued at $212,000. First Trust Advisors LP raised its stake in shares of Dianthus Therapeutics by 42.1% in the third quarter. First Trust Advisors LP now owns 133,810 shares of the company’s stock valued at $11,782,000 after buying an additional 39,658 shares during the period. IFG Advisory LLC raised its stake in shares of Dianthus Therapeutics by 19.1% in the third quarter. IFG Advisory LLC now owns 6,000 shares of the company’s stock valued at $528,000 after buying an additional 961 shares during the period. Fisher Asset Management LLC raised its stake in shares of Dianthus Therapeutics by 1,068.4% in the third quarter. Fisher Asset Management LLC now owns 272,863 shares of the company’s stock valued at $24,026,000 after buying an additional 249,510 shares during the period. Finally, Fifth Third Bancorp lifted its position in shares of Dianthus Therapeutics by 23.6% during the 3rd quarter. Fifth Third Bancorp now owns 676 shares of the company’s stock valued at $60,000 after buying an additional 129 shares during the last quarter. 47.53% of the stock is owned by institutional investors.
Latest Dianthus Therapeutics News
These are some of the DNTH news items that stood out recently:
- Positive Sentiment: Analyst coverage is broadly favorable. A report highlights bullish views on DNTH, and HC Wainwright reiterated a Buy rating with a $158 price target and a bullish FY2026 earnings outlook. The available FY2026 report does not detail the estimate or its rationale. Article: Analysts Are Bullish on These Healthcare Stocks Article: HC Wainwright Has Bullish Estimate for DNTH FY2026 Earnings
- Negative Sentiment: EVP Ryan Savitz sold 124,042 shares from November 9–12 for about $11.2 million, sharply reducing his reported stake. The filings do not state why he sold, but the scale of the transactions may concern investors. Article: Dianthus Therapeutics EVP Sells Shares
Analysts Set New Price Targets
A number of research analysts recently weighed in on the stock. JPMorgan Chase & Co. started coverage on shares of Dianthus Therapeutics in a research report on Friday, September 11th. They set an “overweight” rating and a $135.00 price target on the stock. Citigroup initiated coverage on shares of Dianthus Therapeutics in a research report on Friday, September 4th. They issued a “buy” rating and a $156.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $158.00 price objective on shares of Dianthus Therapeutics in a research report on Thursday, October 15th. Wedbush increased their price objective on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Finally, Truist Financial lifted their target price on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $128.77.
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.
Recommended Stories
- Five stocks we like better than Dianthus Therapeutics
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
